Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05046015
Other study ID # RD.03.SPR.109799
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date March 2017

Study information

Verified date February 2017
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and fissured diabetic foot skin. Specific issues are: Are there any differences between the morphological and functional characteristics of dry to very dry and cracked skin foot between diabetic and nondiabetic subjects? What are the effects of a 4-week once daily application of an intensive care foot ointment (urea 10% foot ointment) or foot lotion (10% Urea foot lotion) on the skin barrier and on clinical signs of dryness and fissures?


Description:

A long existing diabetes mellitus type II is often associated with a number of skin changes. Xerosis Cutis is the most common skin alteration. The risk of diabetics of developing a foot ulcer is estimated to be 15%. Very dry and cracked skin represents an additional risk factor, so that adequate skin care is a widely recommended intervention in diabetic patients. But there are only few studies investigating the skin barrier structure and function in diabetic patients. Available study results seem to suggest, that for instance sebum content, stratum corneum hydration, and pH are associated with Diabetes mellitus. The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and fissured diabetic foot skin. Specific issues are: Are there any differences between the morphological and functional characteristics of dry to very dry and cracked skin foot between diabetic and nondiabetic subjects? What are the effects of a 4-week once daily application of an intensive care foot ointment (urea 10% foot ointment) or foot lotion (10% Urea foot lotion) on the skin barrier and on clinical signs of dryness and fissures?


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility diabetics and non-diabetics - Age 40 to 75 years - Moderate (categories 3 and 4), severe (category 5) dry skin according to the classification of Rogers et al. 1989 - Degree of dryness comparable on both feet (maximum 1 category difference) - BMI between 18.5 and 34.9 kg/m2 (normal weight to class I obesity) - Able to understand and comply with the study requirements - additionally only for diabetics: Diabetes mellitus type 2 for at least 3 years according to Patient Exclusion Criteria: - diabetics and non-diabetics - Any kind of adverse foot condition except xerosis like nail injury, ulceration, (suspected) infection including fungal infection - History of adverse foot condition except xerosis and tinea pedis, like nail injury, ulceration, pain - Mild xerosis cutis of feet (categories 1 and 2 according to Rogers et al. 1989) - Severe xerosis cutis of feet (category 6 according to Rogers et al. 1989) - Gait problems - Other non-controlled chronic and/or acute skin disease except xerosis (e.g. atopic dermatitis, psoriasis, tinea pedis) - Unstable chronic systemic disease (e.g. hypertension, renal insufficiency) - Acute systemic disease (e.g. infection) - Body temperature > 38°C - Pain anywhere - Wear of compression stockings at any time - Use of topical steroids - Use of skin care leave-on products on the feet in the previous 2 weeks - Known hypersensitivity or allergy to product ingredients - Drugs that might affect sweating (oral corticosteroids, psychoactive drugs) - Topical treatments other than the study products on the test areas within14 days prior Day 0 and during the course of the study - Pedicure/ medical foot care 14 days prior D 0 and during the course of the study - Any condition/ circumstance (e.g. cognitive impairment, visual impairment) that might interfere with study compliance in the opinion of the investigator - Current participation in another clinical study - Subject is institutionalized because of legal or regulatory order - additionally only for non-diabetics: Diabetes mellitus type 2 according to Patient - additionally only for diabetics: - Charcot osteoarthropathy - Neuropathy tested with a Semmes-Weinstein monofilament (according to Bakker et al. 2012) - Absence of pedal pulses (1) Posterior tibial artery (2) Dorsalis pedis artery

Study Design


Related Conditions & MeSH terms


Intervention

Other:
10% Urea foot lotion
During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser "Cetaphil® Restoraderm Body Wash" and apply the product "Excipial® U10 Lipolotion 10% Urea" once daily in the evening by themselves.
10% Urea foot ointment
During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser "Cetaphil® Restoraderm Body Wash" and apply the product "Excipial® U10 ointment10% Urea" once daily in the evening by themselves.

Locations

Country Name City State
Germany Charité Universitatsmedizin Berlin Berlin

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Stratum corneum hydration Stratum corneum hydration - Measurement using the Corneometer at Day 28 Day 28
Other Skin surface pH Skin surface pH
Measurement using the pH-Meter® Three replicate measurements; according to the Technical Procedures G01_A4_V01
Day 0 , Day 14, Day 28
Other Epidermal thickness Epidermal thickness
Measurement using OCT taking one image/ visit/ test area Mean of three epidermal thickness measurements; according to the Technical Procedures G04_A1_V01 µm
D28
Other Skin surface topography Skin surface topography - Measurement using Visioscan® Day 0, Day 28±2
Other Elasticity/Stiffness Elasticity/Stiffness Measurement using Cutometer® at day 28 Day 28
Other lipids Oxidative stress on lipids Measurement according to sampling method of Synelvia (Version 2) Day 0, Day 28
Other Callus Callus
Clinical evaluation by study investigator
Classification of Callus severity according to Hashmi et al. 2015
Day 0, Day 28
Other Cracks/ Fissures Cracks/ Fissures
Clinical evaluation by study investigator
Classification according to Oe et al. 2012
Day 0, Day 28
Primary Change from Baseline in Overall Dry Skin Score Clinical assessment of the presence or severity of skin dryness using a 7 point scale at the sole of the foot (randomized). A score of '0' indicated normal skin/no sign of dryness, whereas a score of '6' indicates large-scale plates, deep erythematous fissures and cracks Baseline; Day 28±2
Secondary Skin barrier Transepidermal water loss: Measurement using the Tewameter®
Three replicate measurements; according to the Technical Procedures G01_A1_V01 g/m2/h
Day 0, Day 14±1,Day 28±2
See also
  Status Clinical Trial Phase
Completed NCT02216526 - Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents N/A
Completed NCT03824886 - Enhancing SKIN Health and Safety in Aged CARE N/A
Completed NCT02557698 - Effectiveness of Using an Oil Bath Additive N/A
Completed NCT03093597 - Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin N/A
Active, not recruiting NCT03815305 - Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2 Phase 4
Recruiting NCT05639933 - Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors Phase 2
Completed NCT04253704 - Effects of 2% IDL Lotion on Skin Hydration and Transepidermal Water Loss in Females With Dry Skin Phase 1/Phase 2
Completed NCT06178367 - Effectiveness and Safety of Topical Hyaluronic Acid of Different Molecular Weights in Xerotic Skin Treatment Phase 3
Completed NCT04127513 - Comparison of 12% Ammonium Lactate and 10% Urea Cream in Geriatric With Xerosis Cutis Phase 3